Ani Pharmaceuticals Inc (NASDAQ: ANIP)

ANI Pharmaceuticals is a diversified bio pharmaceutical company that develops manufactures and commercializes therapeutics through its Rare Disease Generics and Brands businesses. The company operates in the pharmaceutical industry focusing on specialty and generic drugs.

The company generates revenue primarily from the sale of its generic and branded pharmaceutical products including oral solids, semi solids, liquids, topicals, controlled substances, and potent compounds manufactured at its own facilities or through third party contractors. Key products include Cortrophin Gel, ILUVIEN, YUTIQ and a branded portfolio such as Atacand, Arimidex, Casodex, Inderal LA, Inderal XL, InnoPran XL, Inzirqo, Lithobid, Oxistat, Vancocin and Veregen. The company also earns revenue from distribution agreements where it sells products under its own label that are owned or licensed by third parties.

The company operates through the following segments: Rare Disease and Brands, and Generics and Other.

• Rare Disease and Brands: This segment includes the Cortrophin Gel (ACTH) therapy for autoimmune disorders, the retina franchise comprising ILUVIEN and YUTIQ for diabetic macular edema and non infectious uveitis, and a portfolio of branded products such as Atacand, Arimidex, Casodex, Inderal LA, Inderal XL, InnoPran XL, Inzirqo, Lithobid, Oxistat, Vancocin and Veregen which are marketed through specialty pharmacies and retail channels.

• Generics and Other: This segment offers over 120 generic products spanning oral solids, injectables and other dosage forms focuses on niche opportunities such as paragraph IV filings and competitive generic therapy designations and benefits from internal research and development, acquisitions of ANDAs and NDAs, and the 2021 Novitium acquisition that added pipeline candidates and manufacturing capabilities.

In the generic pharmaceutical market ANI competes with large players such as Teva Pharmaceuticals, Viatris, Sandoz, Novartis, and Lupin while its Rare Disease and Brands segment faces competition from Acthar gel for Cortrophin and from ophthalmic agents like Eylea, Vabysmo, Avastin, Lucentis, Ozurdex and similar products for ILUVIEN. Competitive advantages include a diversified product mix, the ability to manufacture high potency and controlled substances, control over the supply chain, and a niche focused approach.

The company sells its products to a broad range of customers including national wholesalers such as Cencora, Cardinal Health, and McKesson, specialty pharmacies like CVS Specialty and Accredo, retail chains including CVS, Kroger, Walmart, and Walgreens, distributors, group purchasing organizations, hospitals, and other health care providers. In 2025 approximately 53% of net revenues were derived from three customers indicating a concentrated buyer base.